PI3K Pathway in HR+/HER2– Breast Cancer: Testing, Treatment & the Next Wave | Drs. Pistilli & Saura
More from OncoAlert Horizons
OncoAlert’s educational series: two experts on one evolving question in practice, a focus at a time. The next discussion is first.
Adjuvant treatment challenges in early HR+/HER2− breast cancer: the emerging role of next-generation oral SERDs
Dr. Sibylle Loibl and Dr. Rupert Bartsch
Up next. June 15, 2026. 14 minutes.
The new sequencing challenge in HER2+ metastatic breast cancer
Dr. Javier Cortés and Dr. Elisa Agostinetto
June 10, 2026. 17 minutes.
Early HER2+ breast cancer: escalate, de-escalate or personalize?
Dr. Giampaolo Bianchini and Dr. François-Clément Bidard
May 26, 2026. 20 minutes.
What comes after CDK4/6 inhibitors? SERDs, combinations and the future of HR+ advanced breast cancer
Dr. Sherene Loi and Dr. Elisa Agostinetto
May 20, 2026. 14 minutes.